Only one high-risk area remains in Beijing, the European Union wants to buy Redseywe.

treatment concentration lasts 6 months! Gilead announces early data on HIV-1 shell inhibitors; Chinese pharmaceutical olaxita injections are approved for drug registration; Pfizer's new antifungal drug, Ayshacona, is listed in China; Zhengda Qing's Apopopa ethanolamine tablets are listed; and Qinlock, the first four-line drug, has released 3 clinical new dataOn the afternoon of June 6, Beijing held the 143rd press conference on epidemic prevention and controlAt the meeting, Xu Hejian, vice-minister of the Beijing Municipal Committee's Propaganda Department, reported that as of July 5, 15:00, there was only one high-risk area in Beijing, 22 in medium-risk areas and 24 in low-risk areas(CCTV News)JD.com Health and Siemens Medical signed a cooperation agreement, the two sides will be in the field of medical equipment and large-scale medical equipment, based on their respective capabilities and resources, to enhance the service capacity of non-public medical institutionsTHE EUROPEAN UNION'S HEALTH MINISTERS WILL BEGIN TALKS WITH GIELID ON A PROCUREMENT PLAN ON MONDAY LOCAL TIME,It is reported that the procurement plan will include Germany and other EU countriesrecently, Gilead Sciences released data on an ongoing Phase I clinical study at the 23rd International AIDS ConferenceThe study showed that it was working on a new HIV-1 shell function inhibitor lenacapavir (GS-6207) subcutaneous lysual release, with a therapeutic concentration predicted after a single 900 mg dose lasting at least 6 monthsIn this study, lenacapavir had good tolerance and no serious adverse events were reported(Sina Pharmaceutical News), Zynerba Pharmaceuticals recently announced the top line results of a 14-week clinical study (CONNECT-FX) using cannabidiol (CBD) for children and adolescents with brittle X syndrome (FXS)The experimental drug Zygel (ZYN002 CBD gel) failed to reach the primary endpoint and three key secondary endpoints compared to the placebo, but reached the primary endpoint in special analysis in patients with full methylation of the FMR1 gene(Sina Pharmaceutical News)Reding Pharmaceuticals partner Deciphera Pharmaceuticals recently announced new data from the critical phase III INVICTUS study (NCT03353753) of the target anti-cancer drug Qinlock (ripretinib) for the treatment of advanced gastrointestinal interstitial tumorsThe new data come from a progression-free survival and total survival exploratory analysis of patients who switched from placebo to Qinlock treatment as the disease progresses, showing significant clinical benefits after patients switched from placebo to Qinlock treatment(Bio Valley) Gilead Sciences recently announced the HIV triple-combination new drug Biktarvy (Chinese product name: Bitovi ®, generic name: Bicken prono tablets, Bicktravi 50mg/ Ntquatabin 200mg/propofol nofwei 25mg, BIC/ACE A new analysis by the FTC/TAF confirms that the switch to Biktarvy therapy has good efficacy and safety in older populations with a virological inhibition of 65 years of age (n-140), including those with common comorbidities, such as diabetes, hypertension, cardiovascular disease, and blood lipid abnormalities (Biological Valley) Oncopetipes AB recently announced that it has filed a new drug application with the U.S FDA to seek accelerated approval for melphalan flufenson in combination with the treatment of triple-negotiable multiple myeloma in adult patients (Biological Valley) on the 6th, China Pharmaceuticals announced that its wholly-owned subsidiary Tianfang limited received the "Pharmaceutical Registration Approval" approved by the State Drug Administration After examination, the product meets the relevant requirements of drug registration, approves registration, and issues the drug approval number (China Pharmaceutical Bulletin) Fuxiang Pharmaceuticals announced that the company's holding subsidiary Fuxiang (Dalian) Pharmaceutical Co., Ltd has obtained the approval of the State Drug Administration issued the Agaquban injection "drug registration approval." (Fuxiang Pharmaceutical Announcement) recently submitted by Pfizer in China sulfate Aisaconazole capsules and injection of eisaconazole sulfate listing application to be accepted by CDE Esacona is a new antifungal drug developed by Basilea Pharmaceutica, which was approved by the FDA in March 2015 for a product called Cresemba (Pharmaceutical Rubik's Cube) Zhengda Tianqing submitted a four-class generic drug Aiqupopa ethanolamine tablet listing application was accepted by CDE, after The Osaikang the second domestic (Pharma Cube) Otsuka Pharmaceuticals recently announced that its oral vascular pressure innovator Sacha tablets, Samsca oral disintegrating tablets, Samsca 1% granules have been approved by Japanese regulators for a new indications for use in adult patients to treat hyposodium emia caused by antidduretic hormone secretion syndrome (SIADH) (Bio Valley)